Immunohistochemical assay (IHC) to study C-erbB-2 status of breast cancer using monoclonal antibody CIBCgp185

Human Antibodies

Volumn 12, Issue 4, 2003, Pages 123-127

  Meenakshi, A ^a   Kumar, R Suresh ^b   Ganesh, V ^a   Sivakumar, N ^a  

^a CANCER INSTITUTE WIA   (India)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

Breast cancer; C erbB 2; CIBCgp185

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CIBCGP185; PROTEIN ANTIBODY; UNCLASSIFIED DRUG;

ARTICLE; BENIGN TUMOR; BREAST CANCER; BREAST TUMOR; CELL MEMBRANE; CONTROLLED STUDY; DISEASE SEVERITY; FROZEN SECTION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; ONCOGENE C ERB; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; STAINING; TISSUE SECTION; TUMOR CELL;

EID: 2442720099     PISSN: 10932607     EISSN: None     Source Type: Journal    
DOI: 10.3233/hab-2003-12403     Document Type: Article

References (26)

1. T. Akiyama, C. Sudo, M. Ogawara, K. Toshiyama and T. Yamamoto, The product of the C-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity, Science 232 (1986), 1644-1646.
2. J.S. Ross and J.A. Fletcher, The HER-2/Neu Oncogene in breast cancer: Prognostic Factor, Predictive Factor, and Target for therapy, The Oncologist 3 (1998), 237-252.
3. D.J. Slamon, G.M. Clark, S.G. Wong, W.J. Levin, A. Ullrich and W.L. Mcguire, Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene, Science 235 (1985), 177-182.
4. A. Meenakshi, R. Suresh Kumar and N. Sivakumar, Generation of monoclonal antibody CIBCgp185 against C-erbB-2 oncoprotein and its clinical evaluation, Hum Antibod 10 (2001), 101-107.
5. A. Meenakshi, R. Suresh Kumar and N. Sivakumar, ELISA for quantitation of serum C-erbB-2 oncoprotein in breast cancer patients, J. Immunoassay and Immunochemistry 23 (2002), 293-305.
6. A. Piffanelli, R. Dittadi, L. Catozzi, M. Gion, G. Capitanio, M.C. Gelli, A. Brazzale, R. Malagutti, D. Pellizola, A. Menegon, G. Giovannini and G. Gardeini, Determination of ErbB-2 protein in different breast cancer tissues by different methods. Relationships with other biological parameters, Breast Cancer Res Treat 29 (1996), 3-9.
7. M. Ewertz, S.W. Duffy, H.O. Adami, G. Kvale, E. Lund, O. Meirik, A.M. Gaard, I. Soini and H. Tulinius, Age at first birth, parity and risk of breast cancer: A meta analysis of 8 studies from the nordic countries, Int J Cancer 46 (1990), 597-603.
8. J.R. Harris, M.E. Lippman, U. Veronesi and W.C. Willett, Breast Cancer, New Engl J Med 327 (1992), 319-328.
9. B. Rosner and Colditz, Nurse's health study. Log-incidence model of breast cancer incidence, J Natl Cancer Inst 88 (1996), 359-364.
10. S. Tsutsui, S. Onho, S. Mirukami, Y. Hachitanda and S. Oda, Prognostic significance of C-erbB-2 expression in breast cancer, J Surg Oncol 79 (2002), 216-223.
11. R.L. Ridolfi, M.R. Jamehdor and J.M. Arber, HER-2/neu testing in breast carcinoma: a combined immunohistochemical and fluorescence in situ hybridization approach, Mod Pathol 13 (2000), 866-873.
12. R.M. Hudziak, G.D. Lewis, M. Winget, B.M. Fendly, H.M. Shepard and A. Ullrich, P185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor, Mol Cell Biol 9 (1989), 1165-1172.
13. M.A. Cobleigh, C.L. Vogel, D. Tripathy, J.N. Robert, S. Scholl, L. Fehrenbacher, J.M. Wolter, V. Paton, S. Shak, G. Lieberman and D.J. Slamon, Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2 overexpressing metastatic breast cancer that has progresses after chemotherapy for metastatic disease, J Clin Oncol 17 (1999), 2639-2648.
14. J. Horton, HER2 and Trastuzumab in breast cancer, Cancer Control 8 (2001), 103-110.
15. B.M. Kerns, J.C. Pence, G. Hupur, R.B. Kinney and J.D. Iglehart, C-erbB-2 expression, in breast cancer, detected by immunoblotting, and immunohistochemistry, J. Histochem and Cytochem 38 (1990), 1823-1830.
16. D.M. Barnes, G.A. Lammie, R.R. Miilis, W.L. Gullick, D.S. Allen and D.G. Altman, An immunohistochemical evaluation of C-erbB-2 expression in human breast carcinoma, Br. J. Cancer 58 (1998), 448-452.
17. A. Lebeau, D. Deimling, C. Kaltz, A. Sendelhofert, A. Iff, B. Luthardt, M. Untch and U. Lohrs, HER-2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization, J Clin Oncol 19 (2001), 354-363.
18. D. Vernimmen, M. Gueders, S. Pisvin, P. Delvenne and R. Winkler, Different mechanisms are implicated in ERBB-2 gene overexpression in breast and in other cancers, Br. J. Cancer 89 (2003), 899-906.
19. H. Hofler, R.A. DeLellies and H.J. Wolfe, In situ hybridization and immunohistochemistry, in: Advances in Immunohistochemistry, Ronald A Delellies, ed, Raven press, New York, 1988, pp. 47-66.
20. F. Revellion, J. Bonneterre and J.P. Peyrat, ERBB-2 oncogene in human breast cancer and its clinical significance, Eur J Cancer 34 (1998), 791-808.
21. H. Tsuda, F. Akiyama, H. Terasaki, T. Hasegawa, M. Kurosumi, M. Shimadzu, S. Yamamori and G. Sakamoto, Detection of HER-2/neu (c-erb B-2) DNA amplification in primary breast carcinoma, Cancer 92 (2001), 2965-2974.
22. T.W. Jacobs, A.M. Gown, H. Yazji, M.J. Barnes and S.J. Schnitt, Specificity of Hercep test in determining HER-2/neu status of breast cancers using United states Food and Drug Administration Currency Sign Capproved scoring system, J Clin Oncol 17 (1999), 1983-1987.
23. J.S. Ross and J.A. Fletcher, HER-2/neu (C-erbB-2) gene and protein in breast cancer, Am J Clin Pathol 112 (1999), S53-S67.
24. M.F. Press, G. Hung, G.W. Godolphin and D.J. Slamon, Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression, Cancer Res 54 (1994), 2771-2777.
25. R.R. Tubbs, J.D. Pettay, P.C. Roche, M.H. Stoler, R.B. Jenkins and T.M. Grogen, Discrepancies in clinical laboratory testing of eligibility of trastuzumab therapy: apparent immunohistochemical false positives do not get the message, J Clin Oncol 19 (2001), 2714-2721.
26. R.L. Ridolfi, M.R. Jamehdor and J.M. Arber, HER-2/neu testing in breast carcinoma: a combined immunohistochemical and fluorescence in situ hybridization approach, Mod Pathol 13 (2000), 866-873.